Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Ifosfamide-containing Regimens for Treating Patients with Osteosarcomas

  • Li, Yan-Yan (Department of Neurology, The Second People Hospital of Mudanjiang) ;
  • Jiang, Xiao-Ming (Intensive Care Unit.) ;
  • Dong, Yi-Guo (Department of Radiology, Hongqi Hospital, Mudanjiang Medical University) ;
  • Xu, Gang (Department of Orthopaedics, Hongqi Hospital, Mudanjiang Medical University) ;
  • Ma, Yu-Bo (Department of Orthopaedics, Hongqi Hospital, Mudanjiang Medical University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide-containing regimen in treating patients with osteosarcoma. Methods: Clinical studies evaluating the efficacy and safety of Ifosfamide-containing regimen on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: When ifosfamide-containing regimens were evaluated, 4 clinical studies which including 134 patients with osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 44.8% (60/134) in ifosfamide-containing regimens. Major adverse effects were neutropenia, leukopenia, and fatigue inIfosfamide-containing regimens; No treatment related death occurred in cantharidin combined regimens. Conclusion: This systemic analysis suggests that ifosfamide-containing regimens are associated with good response rate and acceptable toxicity in treating patients with osteosarcoma, but this result should be confirmed by randomized clinical trials.

Keywords

References

  1. Bacci G, Picci P, Ferrari S, et al (1993). Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremity: results in 164 patients preoperatively treated with high doses of methotrexate, followed by cisplatin and doxorubicin. Cancer, 72, 1216-26.
  2. Bao YP, Yi Y, Peng LL, et al (2013). Roles of microRNA-206 in osteosarcoma pathogenesis and progression. Asian Pac J Cancer Prev, 14, 3751-5. https://doi.org/10.7314/APJCP.2013.14.6.3751
  3. Basaran M1, Bavbek ES, Saglam S, et al (2007). A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology, 72, 255-60. https://doi.org/10.1159/000113017
  4. Bramwell VH, Burgers M, Sneath R, et al (1992). A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 10, 1579-91.
  5. Cao ZQ, Shen Z, Huang WY (2013). MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. Asian Pac J Cancer Prev, 14, 7081-4. https://doi.org/10.7314/APJCP.2013.14.12.7081
  6. Chen H, Jiang HZ, Li YC, et al (2014). Antitumor constituents from Anthriscus sylvestris (L.) Hoffm. Asian Pac J Cancer Prev, 15, 2803-7. https://doi.org/10.7314/APJCP.2014.15.6.2803
  7. Diao CY, Guo HB, Ouyang YR, et al (2014). Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev, 15, 1817-22. https://doi.org/10.7314/APJCP.2014.15.4.1817
  8. Ebeling P, Eisele L, Schuett P, et al (2008). Docetaxel and gemcitabine in the treatment of soft tissue sarcoma-a single-center experience. Onkologie, 31, 11-6.
  9. Fox E1, Patel S, Wathen JK, et al (2012). Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 17, 321. https://doi.org/10.1634/theoncologist.2010-0265
  10. Fuchs N, Bielack SS, Epler D, et al (1998). Long-term results of the cooperative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 9, 893-9. https://doi.org/10.1023/A:1008391103132
  11. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W (1996). Excision of 20, 20-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res, 56, 4453-9.
  12. Harris MB1, Cantor AB, Goorin AM, et al (1995). Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol, 24, 87-92. https://doi.org/10.1002/mpo.2950240205
  13. He A1, Qi W, Huang Y, et al (2014). Comparison of pirarubicinbased versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. Int J Clin Oncol, 18, 498-505.
  14. He JP, Hao Y, Wang XL, et al (2014). Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev, 15, 5967-76. https://doi.org/10.7314/APJCP.2014.15.15.5967
  15. He ML, Wu Y, Zhao JM, et al (2013). PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prev, 14, 5117-22. https://doi.org/10.7314/APJCP.2013.14.9.5117
  16. Hensley ML, Maki R, Venkatraman E, et al (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20, 2824-31. https://doi.org/10.1200/JCO.2002.11.050
  17. Jia J, Tian Q, Liu Y, et al (2013). Interactive effect of bisphenol A (BPA) exposure with -22G/C polymorphism in LOX gene on the risk of osteosarcoma. Asian Pac J Cancer Prev, 14, 3805-8. https://doi.org/10.7314/APJCP.2013.14.6.3805
  18. Jiang W, Huang Y, Wang JP, et al (2013). The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pac J Cancer Prev, 14, 4615-9. https://doi.org/10.7314/APJCP.2013.14.8.4615
  19. Kudawara I1, Aoki Y, Ueda T, et al (2013). Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in nonmetastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother, 25, 41-8. https://doi.org/10.1179/1973947812Y.0000000055
  20. Leu KM, Ostruszka LJ, Shewach D, et al (2004). Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol, 22, 1706-12. https://doi.org/10.1200/JCO.2004.08.043
  21. Lin F, Wang Q, Yu W, et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5. https://doi.org/10.1111/j.1743-7563.2011.01406.x
  22. Lorigan P, Verweij J, Papai Z, et al et al (2007). Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clini Onco, 25, 3144-50. https://doi.org/10.1200/JCO.2006.09.7717
  23. Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63. https://doi.org/10.1200/JCO.2006.10.4117
  24. McTiernan A, Whelan JS (2004). A phase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma, 8, 71-6. https://doi.org/10.1155/2004/762736
  25. Mora J, Cruz CO, Parareda A, de Torres C (2009). Treatment of relapsed refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol, 31, 723-9. https://doi.org/10.1097/MPH.0b013e3181b2598c
  26. Nagarajan R, Weigel BJ, Thompson RC, Perentesis JP (2003). Osteosarcoma in the first decade of life. Med Pediatr Oncol, 41, 480-3. https://doi.org/10.1002/mpo.10403
  27. Okuno S, Edmonson J, Mahoney M, et al (2002). Phase II trial of gemcitabine in advanced sarcomas. Cancer, 94, 3225-9. https://doi.org/10.1002/cncr.10602
  28. Provisor AJ, Ettinger LJ, Nachman JB, et al (1997). Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol, 15, 76-84.
  29. Ricotti L, Tesei A, De Paola F, et al (2003). In vitro scheduledependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res, 9, 900-5.
  30. Ringel I, Horwitz SB (1991). Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst, 83, 288-91. https://doi.org/10.1093/jnci/83.4.288
  31. Seker MM, Seker A, Aksoy S, et al (2014). Clinicopathologic features and prognosis of osteosarcoma in Turkish adults. Asian Pac J Cancer Prev, 15, 3537-40. https://doi.org/10.7314/APJCP.2014.15.8.3537
  32. Sleijfer S, Ouali M, van Glabbeke M, et al (2010). Prognostic and predictive factors for outcome to first-line ifosfamidecontaining chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Euro J Cancer, 46, 72-83. https://doi.org/10.1016/j.ejca.2009.09.022
  33. Song BS, Seo J, Kim DH, et al (2014). Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer, 61, 1376-81. https://doi.org/10.1002/pbc.25035
  34. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  35. Wang CK, Yu XD, Li Q, et al (2013). Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line. Asian Pac J Cancer Prev, 14, 4651-4. https://doi.org/10.7314/APJCP.2013.14.8.4651
  36. Yang J, Wang ZG, Cai HQ, et al (2013). Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev, 14, 4595-8. https://doi.org/10.7314/APJCP.2013.14.8.4595
  37. Zhao H, Yao Y, Wang Z, et al (2010). Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother, 22, 119-24. https://doi.org/10.1179/joc.2010.22.2.119

Cited by

  1. Association of Metastasis with Clinicopathological Data in Mexican Patients with Osteosarcoma, Giant Cell Tumor of Bone and Chondrosarcoma vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7689
  2. Continuous-infusion Ifosfamide and Doxorubicin Combination as Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2391